MIF

MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference

Retrieved on: 
Friday, April 22, 2022
Code, ALS, Annual report, Acute respiratory distress syndrome, Substance dependence, Idiopathic pulmonary fibrosis, Nasdaq, Ophthalmology, B. Riley Financial, Non-alcoholic fatty liver disease, DCM, Multiple sclerosis, U.S. Securities and Exchange Commission, Tokyo Stock Exchange, Security (finance), NASDAQ, JD/MBA, MD, MIF, Private Securities Litigation Reform Act, GLOBE, Doctor of Philosophy, Glioblastoma, Chemotherapy-induced peripheral neuropathy, Patient, Form 10-K, Intellectual property, Conference, CIPN, Amyotrophic lateral sclerosis, Failure, Form 8-K, PDE4, Neurodegeneration, NAFLD, IPF, FDA, MS, Risk, Pharmaceutical industry

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).

Key Points: 
  • MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
  • In addition, MN-166 (ibudilast) is being evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
  • MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

Retrieved on: 
Thursday, April 21, 2022
Code, Nasdaq, Herbert Irving Comprehensive Cancer Center, Tokyo Stock Exchange, NASDAQ, Mothers (Tokyo Stock Exchange), Columbia University Irving Medical Center, MD, Metastasis, MIF, Exosome, Associate, GLOBE, Hematology-Oncology and Stem Cell Transplantation Research Center, Doctor of Philosophy, Columbia University, Cell biology, Melanoma, UM, Hepatocyte, Macrophage migration inhibitory factor, Pathology, Columbia University Vagelos College of Physicians and Surgeons, Uveal melanoma, Physician, Cytokine, Molecular Cancer Research, Uvea, Research, Pharmaceutical industry, Vaccine, Medicine, Surgeon

The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.

Key Points: 
  • The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.
  • Key take-aways in the publication include:
    Uveal melanoma exosomes (UM-exo) induce activation of cell signaling pathways and the release of cytokines and growth factors from hepatocytes.
  • MIF blockade inhibited UM cell migration in co-cultures with exosome-stimulated hepatocytes and prevented the development of metastases in vivo.
  • This study provided the first in vivo evidence that MIF inhibition may serve as a novel adjuvant drug therapy to prevent metastasis in uveal melanoma.

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, April 13, 2022
Code, Soft tissue injury, ALS, Annual report, Acute respiratory distress syndrome, Substance dependence, Idiopathic pulmonary fibrosis, Carbon, Nasdaq, Non-alcoholic fatty liver disease, DCM, Multiple sclerosis, U.S. Securities and Exchange Commission, COVID-19, Tokyo Stock Exchange, Security (finance), NASDAQ, Oxygen saturation (medicine), MD, MIF, Infection, Private Securities Litigation Reform Act, GLOBE, Glioblastoma, Death, Chemotherapy-induced peripheral neuropathy, Patient, Form 10-K, Inflammation, Atmosphere, Intellectual property, CIPN, NIAID, Amyotrophic lateral sclerosis, Failure, Form 8-K, PDE4, Neurodegeneration, NAFLD, Oxygen, Coronavirus, IPF, FDA, Pneumonia, MS, Risk, Virus, MPH, Pharmaceutical industry, Doctor of Philosophy

Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "The last enrolled patients last visit has been completed.

Key Points: 
  • Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "The last enrolled patients last visit has been completed.
  • Acute respiratory distress syndrome (ARDS) is a frequently lethal lung condition caused by excessive inflammation for which there are no effective therapies beyond supportive care.
  • In addition, MN-166 (ibudilast) is being evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
  • MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, patients at risk of developing acute respiratory distress syndrome (ARDS), and substance dependence.

MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

Retrieved on: 
Friday, April 8, 2022
Brain, Private Securities Litigation Reform Act, Risk, Amyotrophic lateral sclerosis, Experiment, Multiple sclerosis, University of California, San Diego Performance-Based Skills Assessment, MIF, DCM, Form 10-K, Lists of diseases, Glioblastoma, NASDAQ, Substance dependence, Idiopathic pulmonary fibrosis, Code, Form 8-K, Alcoholism, NIAAA, Neurodegeneration, Patient, Tokyo Stock Exchange, Annual report, ALS, Crave, Camp, MPH, Alcoholism: Clinical and Experimental Research, Failure, PDE10, U.S. Securities and Exchange Commission, Psychiatry, PDE4, MD, Disorder, IPF, NASH, Security (finance), AUD, MS, CIPN, DDA, Intellectual property, Nucleus accumbens, GLOBE, Drinking, Fatty liver disease, FDA, Acute respiratory distress syndrome, Nasdaq, University, Disease, Chemotherapy-induced peripheral neuropathy, Pharmaceutical industry, Beer, Doctor of Philosophy

Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.

Key Points: 
  • Eligible participants were randomized to MN-166 (ibudilast) or matched placebo and completed daily diary assessments (DDAs) during the two-week period.
  • Multilevel models compared the effects of MN-166 (ibudilast) and placebo on subjective alcohol response.
  • We are pleased that the results of this secondary analysis are consistent with the findings from the primary analysis.
  • Alcohol use disorder (AUD) is a prevalent and disabling psychiatric disorder with limited treatment options.

Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

Retrieved on: 
Monday, April 11, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Company, Drug development, Compugen (Israeli company), Biomarker, MIF, CLIA, DIA, Immunotherapy, NeoGenomics, Patient, GLP, AACR, Research, Proteome, Environment, American Association, Proteoform, Cancer, Norwich Pharma Services, Health, NEO, Marie Cassidy, Laboratory, Software, Association, CAP, GCP, Oncology, HRM, Nasdaq, Melanoma, Physician, Drug discovery, Solution, Information services, Data-independent acquisition, Protein, Proteomics, Partnership, Medical imaging, Pharmaceutical industry

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.

Key Points: 
  • Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.
  • The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
  • At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development, said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys.
  • We are excited to now combine our proteomics platforms with NeoGenomics immuno-profiling platform to advance our biopharma partners oncology drug development programs.

OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Company, Colon, MIF, Therapy, Degenerative disease, Leadership, Toxicity, II, Mouse, AACR, CDT, American Association, Conference, Cancer, CEO, CTO, Poster, Association, American Association for Cancer Research, Knowledge, Cell, Annual general meeting, Prostate cancer, Drug discovery, Attention, Cell Press, Patient, Pharmaceutical industry

Conference participants can access the data in both a poster format and an online oral presentation via the conference website .

Key Points: 
  • Conference participants can access the data in both a poster format and an online oral presentation via the conference website .
  • The poster #313 will be presented on Sunday, April 10 in the poster session Antibodies and Immune Therapies, from 1:30 5:00 pm CDT.
  • The preclinical data presented at AACR further validates our approach as we prepare to initiate the evaluation of ON203 in a Phase I clinical trial in patients with solid tumors.
  • The poster will be available on OncoOnes website upon conclusion of the AACR 2022 Annual Meeting.

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

Retrieved on: 
Thursday, April 7, 2022
Data Management, Health, Technology, Other Health, Software, General Health, Biotechnology, Adoption, MIF, LinkedIn, Data management, MSK, Patient, Tumor microenvironment, Research, Pathology, Memorial Sloan Kettering Cancer Center, Precision medicine, CEO, Marie Cassidy, Paige, Industry, Technology, Review, Twitter, Goal, Oncology, Workflow, Solution, FDA, AI, Deep learning, Partnership, Medical device, Medical imaging

The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.

Key Points: 
  • The fast, zero-footprint, scanner-agnostic viewer, storage capabilities and AI-based diagnostic software help pathologists review cases and support their overall workflow.
  • Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique platform agnostic solutions for use in both mIF imaging and spatial phenomics.
  • By uniting two platform-agnostic technologies, we are well-positioned to enable broad adoption of our AI-powered biomarker imaging solutions.
  • Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022

Retrieved on: 
Wednesday, April 6, 2022
Technology, Research, Other Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, MIF, Leadership, Tumor microenvironment, AACR, Research, Pathology, American Association, ISP, Cancer, Precision medicine, RNA, Neoplasm, AstraZeneca, 2021 Essex County Council election, Industry, Association, American Association for Cancer Research, Workflow, Solution, Titan Mare Explorer, GEMM, Bayer, Merck, Medical imaging, Takeda, Fluidigm

The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME.

Key Points: 
  • The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME.
  • Ultivue will also host their 2nd annual Biomarker Insights Summit on April 8th, 2022, ahead of the annual AACR meeting.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.
  • Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research.

Moonshoot Finance Announces Auto-Staking and Auto-Compounding Protocol

Retrieved on: 
Wednesday, March 23, 2022
MALE, MIF, Fire pit, Investment, APY, Growth, BNB, Â, KYC, Launch pad, NFT, GLOBE, Treasury, MST, Cryptocurrency

New York, NY, March 23, 2022 (GLOBE NEWSWIRE) -- The Moonshoot Finance team is pleased to announce its auto-staking and auto-compounding protocol that offers the higher revenue.

Key Points: 
  • New York, NY, March 23, 2022 (GLOBE NEWSWIRE) -- The Moonshoot Finance team is pleased to announce its auto-staking and auto-compounding protocol that offers the higher revenue.
  • While highlighting the benefits of the protocol, the developer team noted that it offers the following:
    Automatic staking and compounding in each users wallet.
  • The Fire Pit grows in size according to the volume; thereby reducing the tokens circulating supply while stabilizing the Moonshoot Protocol.
  • Thats also a brilliant way to maintain protocol stability and ensure that the APY is upheld throughout the Moonshoots lifespan.

The Multiple Myeloma Research Foundation (MMRF) Names George Mulligan, Ph.D., Chief Scientific Officer

Retrieved on: 
Wednesday, March 30, 2022
Science, Other Philanthropy, Other Science, Research, General Health, Health, Philanthropy, Foundation, MMRC, Drug development, MIF, Bortezomib, Translational medicine, Immunotherapy, Research, Multiple myeloma, Genomics, Cancer, Multiple Myeloma Research Foundation, Precision medicine, CEO, Tissue, Communication, MMRF, Industry, Knowledge, Multiple Myeloma Research Consortium, Solution, FDA, Patient, Management, Pharmaceutical industry, Medical device

The Multiple Myeloma Research Foundation (MMRF) has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately.
  • His previous roles include serving as the Chief Scientific Officer at Mitobridge where he drove the overall scientific and translational strategy for its mitochondrial platform and clinical compounds.
  • We are thrilled to have Dr. Mulligan join our team as Chief Scientific Officer, said Michael Andreini, President and CEO, the MMRF.
  • A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.